Red Blood Cells are Appropriate Carrier for Coagulation Factor VIII

AIMS: Factor VIII (FVIII) replacement therapy remains a primary treatment for hemophilia A, however, the development of FVIII antibodies (inhibitors) and short half-life of the FVIII products are the major complications. Erythrocytes may prevent rapid removal of drugs from plasma. Erythrocytes are b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sayyadipour, Fatemeh, Amirizadeh, Naser, Oodi, Arezoo, Khalili, Masoud, Saba, Fakhredin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360916/
https://www.ncbi.nlm.nih.gov/pubmed/31533604
http://dx.doi.org/10.2174/1871529X19666190918141859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360916/
https://www.ncbi.nlm.nih.gov/pubmed/31533604
http://dx.doi.org/10.2174/1871529X19666190918141859

Ejemplares similares